SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bill Wexler who wrote (405)12/22/1997 11:10:00 PM
From: Brander  Read Replies (1) of 834
 
Bill, you said that "The FDA has nothing to do with this one way or the other."

What about this: "TBC (TXB) submitted a new drug application (''NDA'') to the U.S. Food and Drug Administration (''FDA'') for NOVASTAN(R) as anticoagulant therapy in patients with heparin-induced thrombocytopenia (''HIT''), which was accepted during October. The FDA
granted priority review status to the NDA, and the Company anticipates a decision on the approval of the NDA during the first half of 1998.

If TXB was a scam company, do you really think the FDA would grant their drug priority review status?

Brad
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News